ATE443057T1 - Phenylsulfonderivate und deren verwendung bei der behandlung von zns-erkrankungen - Google Patents

Phenylsulfonderivate und deren verwendung bei der behandlung von zns-erkrankungen

Info

Publication number
ATE443057T1
ATE443057T1 AT04718657T AT04718657T ATE443057T1 AT E443057 T1 ATE443057 T1 AT E443057T1 AT 04718657 T AT04718657 T AT 04718657T AT 04718657 T AT04718657 T AT 04718657T AT E443057 T1 ATE443057 T1 AT E443057T1
Authority
AT
Austria
Prior art keywords
treatment
phenylsulfone
derivatives
cns diseases
cns
Prior art date
Application number
AT04718657T
Other languages
English (en)
Inventor
Gregor James Macdonald
Mervyn Thompson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE443057T1 publication Critical patent/ATE443057T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04718657T 2003-03-11 2004-03-09 Phenylsulfonderivate und deren verwendung bei der behandlung von zns-erkrankungen ATE443057T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305575.3A GB0305575D0 (en) 2003-03-11 2003-03-11 Novel compounds
PCT/EP2004/002554 WO2004080986A1 (en) 2003-03-11 2004-03-09 Phenyl sulfone derivatives and their use in the treatment of cns disorders

Publications (1)

Publication Number Publication Date
ATE443057T1 true ATE443057T1 (de) 2009-10-15

Family

ID=9954569

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718657T ATE443057T1 (de) 2003-03-11 2004-03-09 Phenylsulfonderivate und deren verwendung bei der behandlung von zns-erkrankungen

Country Status (8)

Country Link
US (4) US7262188B2 (de)
EP (1) EP1608635B1 (de)
JP (1) JP2006519812A (de)
AT (1) ATE443057T1 (de)
DE (1) DE602004023185D1 (de)
ES (1) ES2333720T3 (de)
GB (1) GB0305575D0 (de)
WO (1) WO2004080986A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009318A (es) * 2002-03-27 2005-01-25 Glaxo Group Ltd Derivados de quinolina y su uso como ligados 5-ht6.
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP1676842A1 (de) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Nitrosubstituierte Phenylpiperazinverbindungen, ihre Herstellung und Verwendung in Arzneimitteln
JP2010521516A (ja) * 2007-03-21 2010-06-24 グラクソ グループ リミテッド 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2759491A1 (en) 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
PE20120881A1 (es) 2009-04-30 2012-08-24 AbbVie Deutschland GmbH and Co KG Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
SG11201700655WA (en) * 2014-08-07 2017-02-27 Vitae Pharmaceuticals Inc Piperazine derivatives as liver x receptor modulators
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN110117264B (zh) * 2018-02-06 2023-06-09 广东东阳光药业有限公司 苯基砜衍生物及其在药物上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238994A1 (de) 1992-11-19 1994-05-26 Basf Ag Aniline als Markierungsmittel für Mineralöle
US5665739A (en) 1992-12-15 1997-09-09 Hoechst Aktiengesellschaft Substituted benzoylguanidines, process and their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them
FR2712591B1 (fr) 1993-11-19 1996-02-09 Pf Medicament Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
EE200000016A (et) 1997-07-10 2000-10-16 Janssen Pharmaceutica N.V. IL-5 inhibeerivad 6-asauratsiili derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, retseptori markeerimismeetod ja organi visualiseerimismeetod
BR9810991A (pt) * 1997-07-11 2000-08-08 Smithkline Beecham Plc Novos compostos
ES2193607T3 (es) 1998-01-16 2003-11-01 Hoffmann La Roche Derivados de benzosulfona .
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
IL159880A0 (en) 2001-08-10 2004-06-20 Hoffmann La Roche Arylsulfonyl derivatives with 5-ht6 receptor affinity
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN100412073C (zh) * 2002-05-28 2008-08-20 三维药物公司 新颖的噻吩脒、其组合物和治疗补体-介导疾病与病症的方法
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
US20070275979A1 (en) 2007-11-29
EP1608635B1 (de) 2009-09-16
US20060281757A1 (en) 2006-12-14
JP2006519812A (ja) 2006-08-31
US7262188B2 (en) 2007-08-28
DE602004023185D1 (de) 2009-10-29
WO2004080986A1 (en) 2004-09-23
US7439245B2 (en) 2008-10-21
US20080214571A1 (en) 2008-09-04
EP1608635A1 (de) 2005-12-28
US20090012099A1 (en) 2009-01-08
ES2333720T3 (es) 2010-02-26
GB0305575D0 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
ATE443057T1 (de) Phenylsulfonderivate und deren verwendung bei der behandlung von zns-erkrankungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
NO20053263L (no) Hydroksyetylaminderivater for behandling av Alzheimers sykdom.
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
DE19680619D2 (de) Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
ATE345792T1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60144064D1 (de) Sulfone, die die aktivität von gamma-secretase modulieren
ATE239680T1 (de) Sulfonamid derivate und deren verwendung
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
NO20054744L (no) Behandling av Alzheimers sykdom
ATE126227T1 (de) Verwendung von (omega-(4-(2-pyrimidinyl)-1- piperazinyl)-alkyl)1h-azolderivate für die herstellung von heilmitteln zur behandlung von störungen kognitiver funktionen.
ATE414090T1 (de) Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
DE69525633D1 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
DE60213450D1 (de) Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist
DE60120961D1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
ATE148344T1 (de) Verwendung von 15-dehydroxy-16-oxoprostaglandin bei der behandlung von allergischen erkrankungen
DE69911373D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE369849T1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties